CardioNet, Inc. Announces Launch of its iPad App for Mobile Cardiac Outpatient Telemetry (MCOT)
November 28 2012 - 12:57PM
Business Wire
CardioNet, Inc. (NASDAQ:BEAT), the leading wireless medical
technology company focused on diagnosing and monitoring cardiac
arrhythmias, announced today the release of a new application for
the iPad, designed to provide physicians and their support staff
easy access to the cardiac monitoring services at CardioNet.
Joseph Capper, CEO and President for CardioNet commented, “We
are pleased to offer the thousands of physicians who prescribe
MCOT, the most advanced cardiac monitoring system on the market,
easier accessibility to patient data. Starting today, we launched
an iPad application which allows health care providers to instantly
access cardiac monitoring reports on-line. We believe that making
the most precise mobile cardiac-related information available to
physicians at their fingertips, in a user-friendly format, is a
powerful tool that will benefit patients, payors and physicians
alike.”
The new CardioNet Access App, currently available for free
download at the Apple store, will enable physicians to save, print
and send patient reports from the convenience of their iPad.
About CardioNet
CardioNet is the leading provider of ambulatory, continuous,
real-time outpatient management solutions for monitoring relevant
and timely clinical information regarding an individual’s health.
CardioNet’s initial efforts are focused on the diagnosis and
monitoring of cardiac arrhythmias, or heart rhythm disorders, with
a solution that it markets as Mobile Cardiac Outpatient TelemetryTM
(MCOTTM). More information can be found at
http://www.cardionet.com.
Forward-Looking Statements
This document includes certain forward-looking statements within
the meaning of the “Safe Harbor” provisions of the Private
Securities Litigation Reform Act of 1995 regarding, among other
things, our growth prospects, the prospects for our products and
our confidence in the Company’s future. These statements may be
identified by words such as “expect,” “may,” “anticipate,”
“possible,” “estimate,” “potential,” “intend,” “plan,” “believe,”
“forecast,” “promises” and other words and terms of similar
meaning. Such forward-looking statements are based on current
expectations and involve inherent risks and uncertainties,
including important factors that could delay, divert, or change any
of them, and could cause actual outcomes and results to differ
materially from current expectations. These factors include, among
other things, effectiveness of our efforts to address operational
initiatives, including cost savings initiatives that affect our
business, changes to insurance coverage, relationships with our
government and commercial payors and reimbursement levels for our
products, the success of our sales and marketing initiatives, our
ability to attract and retain talented executive management and
sales personnel, our ability to identify acquisition candidates,
acquire them on attractive terms and integrate their operations
into our business, the commercialization of new products, market
factors, internal research and development initiatives, partnered
research and development initiatives, competitive product
development, changes in governmental regulations and legislation,
the continued consolidation of payors, acceptance of our new
products and services and patent protection, adverse regulatory
action and litigation success. For further details and a discussion
of these and other risks and uncertainties, please see our public
filings with the Securities and Exchange Commission, including our
latest periodic reports on Form 10-K and 10-Q. We undertake no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future events, or
otherwise.
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jun 2024 to Jul 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jul 2023 to Jul 2024